We recently published a list of 15 Cheapest Stocks Insiders Are Buying In March. In this article, we are going to take a look ...

THIO has gained its generic name and preclinical data on a different form of the cancer drug suggests it could improve ...

THIO is presently developed as a third line of treatment for NSCLC for patients that are resistant to checkpoint inhibitors and chemotherapy. About MAIA Biotechnology, Inc. MAIA is a targeted ...

MAIA Biotechnology, Inc., (NYSE American ... name for its lead molecule THIO, a telomere-targeting anticancer agent in clinical development as a first-in-class treatment for advanced non-small ...

MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug ...

(RTTNews) - MAIA Biotechnology Inc. (MAIA), on Wednesday ... nonproprietary name for its investigational anticancer agent, THIO. The approval is an important step in the regulatory process ...

MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract ...

3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever MAIA Biotechnology ... company's lead product candidate is THIO, a telomere-targeting agent that ...

MAIA Biotechnology (MAIA) announced the publication of preclinical data for its lead proprietary telomere-targeting THIO dimer in the ...

MAIA Biotechnology Receives USAN Council Approval for "Ateganosine" as Nonproprietary Name for Anticancer Agent THIO ...